Lungs News and Research

RSS

SBRT effective in primary tumor control, study finds

Many of the world's leading radiation oncologists are employing the unique capabilities of SBRT to treat a variety of cancers that often have defied conventional radiation therapy techniques. A multitude of studies evaluating SBRT are ongoing and investigators are publishing articles that demonstrate the effectiveness of this technique. Two studies led by renowned radiation oncologists were conducted at centers that use Elekta SBRT technology, and their results were published recently.

From Elekta 2 Apr 2010

Study reveals less invasive procedure beneficial for patients with sufficient lung function

Research published in the April edition of the Journal of Thoracic Oncology sought to compare the outcomes of a sleeve lobectomy and a pneumonectomy procedure, in order to determine which is a more acceptable standard treatment for patients with non-small cell lung cancer.

2 Apr 2010

Study promises new combination cancer therapy for drug resistance

Results reported in the April 2nd issue of the journal Cell, a Cell Press publication, reveal a new source for the drug resistance that crops up all too often and quickly in the tumors of cancer patients undergoing therapy.

2 Apr 2010

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).

2 Apr 2010

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

A drug already prescribed to shrink benign, enlarged prostates has been shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease, a large international trial has found. Results are reported April 1 in the New England Journal of Medicine.

2 Apr 2010

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

ImmunoCellular Therapeutics announced today that it has filed its Annual Report with the Securities and Exchange Commission for the period ended December 31, 2009 on Form 10-K.

1 Apr 2010

Patient-safety incidents: 10% died

Nearly one million patient-safety incidents occurred among Medicare patients over the years 2006, 2007, 2008, a figure virtually unchanged since last year's annual study of patient safety by HealthGrades, the leading independent healthcare ratings organization. In all, the incidents were associated with $8.9 billion in costs. One in ten patients -- 99,180 individuals -- experiencing a patient-safety incident died as a result, the study found.

1 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Mtb fine-tunes behaviour to escape detection and causes TB

Mycobacterium tuberculosis (Mtb) possesses extraordinary survival ability by masking itself from the host immune system and persisting for decades inside the host. Speaking at the Society for General Microbiology's spring meeting in Edinburgh today, Dr Kristine Arnvig provides further insight into how the bacterium causes tuberculosis (TB) by fine-tuning its behaviour in response to its surroundings to escape detection.

1 Apr 2010

Cigarette filters contain pig’s blood

The next time you light up a cigarette you may be puffing on a filter which contains pig’s blood. A recent Dutch research found that pig hemoglobin was being used to make filters of cigarettes more effective in blocking harmful chemicals before they enter the smoker’s lungs.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

ArQule, Inc. today announced that ARQ 197, when used in combination with erlotinib, demonstrated a 66% improvement in median Progression-Free Survival in patients with advanced, refractory non-small cell lung cancer.

31 Mar 2010

Ukraine uses EDAPS Tax Stamp System to control illicit sales of tobacco products

The most recent edition of the authoritative Tobacco Atlas, released by the American Cancer Society and World Lung Foundation, ranks nations on their success in combating illegal sales of cigarettes and tobacco products.

31 Mar 2010

High radon levels in residential buildings can cause lung cancer

About 1900 deaths from lung cancer per year in Germany are due to radon within residential buildings. This was the conclusion reached in the current edition of Deutsches -rzteblatt International by Klaus Schmid of the University of Erlangen-Nuremberg and his coauthors (Dtsch Arztebl Int 2010; 107(11): 181-6).

31 Mar 2010

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

New drugs that are helping fight a multi-front war on cancer may do the same for cardiovascular disease, Medical College of Georgia researchers said.

31 Mar 2010

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Oncolytics Biotech Inc. announced today that the Cancer Therapy & Research Center at the University of Texas Health Science Center has started patient enrolment in a U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with squamous cell carcinoma of the lungs.

30 Mar 2010

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Clinical Data, Inc., today announced results from two Phase I studies of Stedivaze™ (apadenoson), which demonstrated that Stedivaze was safe and well tolerated in patients with asthma and chronic obstructive pulmonary disease (COPD). Stedivaze is a potent and highly selective agonist of the adenosine A2A receptor subtype in development as a pharmacologic stress agent for myocardial perfusion imaging (MPI).

30 Mar 2010

Mutations in gene protecting body leads to development of cancer

An important gene that normally protects the body against cancer can itself cause a variety of cancers depending on the specific mutation that damages it, according to a new study by investigators at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James).

30 Mar 2010

Lungs News and Research

SBRT effective in primary tumor control, study finds

Study reveals less invasive procedure beneficial for patients with sufficient lung function

Study promises new combination cancer therapy for drug resistance

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

International, four-year study finds dutasteride reduces risk of prostate cancer diagnosis in men

ImmunoCellular Therapeutics files Annual Report with Securities and Exchange Commission for 2009

Patient-safety incidents: 10% died

BeaconEquity.com announces investment report featuring OXiGENE

Mtb fine-tunes behaviour to escape detection and causes TB

Cigarette filters contain pig’s blood

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

New medicines to fight diseases of particular concern to African Americans

Rosetta Genomics reports revenues of $150,000 for full-year 2009

ARQ 197 demonstrates 66% improvement in median PFS in patients with advanced NSCLC

Ukraine uses EDAPS Tax Stamp System to control illicit sales of tobacco products

High radon levels in residential buildings can cause lung cancer

Hsp90 inhibitors may help fight cardiovascular disease, say researchers

CTRC initiates patient enrolment in U.S. Phase 2 clinical trial of REOLYSIN

Two Phase I studies of Stedivaze demonstrate safety in patients with asthma and COPD

Mutations in gene protecting body leads to development of cancer

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News